Semi-heterogeneous g-C₃N₄/NaI Dual Catalytic C-C Bond Formation under Visible Light

Hai-Yang Song^a, Jun Jiang^a, Chao Wu^a, Jia-Chen Hou^a, Yu-Han Lu^a, Ke-Li Wang^a, Tian-Bao Yang^b, Wei-Min He^a*

^aSchool of Chemistry and Chemical Engineering, University of South China, Hengyang 421001, China

^bNational Engineering Research Center of Low-Carbon Processing and Utilization of

Forest Biomass, Nanjing Forestry University, Nanjing 210037, China

Email: weiminhe@usc.edu.cn

Table of Content

1. General Information	. S1
2. General Procedure	. S 3
2.1 Typical Procedure for the Synthesis of 3	. S 3
2.2 Control Experiments	. S3
2.3 Procedure for Gram Scale Synthesis of 3aa	. S 4
2.4 Reusability and Stability of Photocatalyst	. S 4
2.5 Effect of Visible Light Irradiation	. S 4
2.6 Calculation of Apparent Quantum Yield	. S6
3. Characterization Data of Products	. S6
4. References	S14
5. ¹ H, ¹³ C and ¹⁹ F NMR Spectra of Products	S15

1. General Information

Unless otherwise noted, all reagents and solvents were obtained from commercial suppliers and used without further purification. GC yield was detected by Agilent GC-MS 8890/5977B. ¹ H NMR spectra were recorded at 500 MHz and ¹³C NMR spectra were recorded at 125 MHz by using a Bruker Avance 500 spectrometer. ¹⁹F NMR data were collected at 471 MHz with complete proton decoupling. Chemical shifts were calibrated using residual undeuterated solvent as an internal reference (¹ H NMR: CDCl₃ 7.26 ppm, ¹³C NMR: CDCl₃ 77.16 ppm,), the chemical shifts (δ) were expressed in ppm and J values were given in Hz. The following abbreviations were used to describe peak splitting patterns when appropriate: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, br = broad. Mass spectra were recorded using a Shimadzu UV-2600 spectrophotomete. The crude products were purified by HPLC (LaboACE LC-5060, Japan Analytical Industry Co., Ltd., Japan) equipped with Jaigel 2.5 HR columns with dichloromethane as the eluent.

The Light Source and the Material of the Irradiation Vessel

Manufacturer: Beijing Rogertech Ltd. Model: RLH-18CU Value: 5836.430 µW/cm²/nm Energy peak wavelength: 453.0 nm Peak width at half-height: 22.1 nm Material of the irradiation vessel: Schlenk flask Not use any filters





• Figure S1. LED spectrum test report



Figure S2. Photo-reactor System

2. General Procedure

2.1 Typical Procedure for the Synthesis of 3

To a 10.0 mL Schlenk flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1** (0.2 mmol), arylhydrazines **2** (0.4 mmol), g-C₃N₄ (15 mg), NaI (0.001 mmol) and EtOH (3.0 mL). The resulting mixture was charged with air. Then the reaction mixture was stirred and irradiated by 8 W blue LED at ambient temperature for about 30 h. The reaction progress was monitored by thin-layer chromatography analysis. After the completion of the reaction, the insolubles were removed by filtration. The filtrate was evaporated under reduced pressure, which was then purified with chromatography column on silica gel (EtOAc: petroleum ether=5:1) to give the corresponding products **3**.

2.2 Control Experiments



- (a) To a 10.0 mL Schlenk flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1a** (0.2 mmol), phenylhydrazine **2a** (0.4 mmol), g-C₃N₄ (15 mg), NaI (0.001 mmol), radical scavenger (TEMPO or α,α -diphenylethylene, 0.4 mmol) and EtOH (3.0 mL). Then the reaction mixture was stirred and irradiated by 8 W blue LED at ambient temperature for about 30 h. The reaction mixture was monitored by GC-MS, only trace amount of **3aa** was detected.
- (b) To a 10.0 mL Schlenk flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1a** (0.2 mmol), phenylhydrazine **2a** (0.4 mmol), I₂ (0.2 mmol) or ICl (0.2 mmol) and EtOH (3.0 mL). Then the reaction mixture was stirred at ambient temperature for about 12 h.

- (c) To a 10.0 mL Schlenk flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1a** (0.2 mmol), phenylhydrazine **2a** (0.4 mmol), g-C₃N₄ (15 mg), NaI (0.001 mmol), *p*-benzoquinone (2.0 mmol) and EtOH (3.0 mL). Then the reaction mixture was stirred and irradiated by 8 W blue LED at ambient temperature for about 30 h. The reaction was monitored by GC-MS, only trace amount of **3aa** was detected.
- (d) To a 10.0 mL Schlenk flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1a** (0.2 mmol), phenylhydrazine **2a** (0.4 mmol), g-C₃N₄ (15 mg), NaI (0.001 mmol), HCO₂NH₄ (2.0 mmol) and EtOH (3.0 mL). Then the reaction mixture was stirred and irradiated by 8 W blue LED at ambient temperature for about 30 h. The reaction was monitored by GC-MS, only trace amount of **3aa** was detected.
- (e) To a 10.0 mL Schlenk flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1a** (0.2 mmol), phenylhydrazine **2a** (0.4 mmol), g-C₃N₄ (15 mg), NaI (0.001 mmol), CCl₄ (2.0 mmol) and EtOH (3.0 mL). Then the reaction mixture was stirred and irradiated by 8 W blue LED at ambient temperature for about 30 h. The reaction was monitored by GC-MS, only trace amount of **3aa** was detected.

2.3 Procedure for Gram Scale Synthesis of 3aa

To a 100 mL round bottom flask equipped with a magnetic stirring bar were added quinoxalin-2(1*H*)-ones **1a** (6 mmol), phenylhydrazine **2a** (12 mmol), g-C₃N₄ (500 mg) NaI (0.034 mmol) and EtOH (50 mL). The resulting mixture was charged with air. Then the reaction mixture was stirred and irradiated by 8 W blue LED at ambient temperature for about 36 h. After the completion of the reaction, the solvent was evaporated under reduced pressure and the residue was purified by HPLC to afford product **3aa** (1.01 g, 72% yield).

2.4 Reusability and Stability of Photocatalyst

The reusability and stability of $g-C_3N_4$ was tested: In a typical procedure, the mixture of quinoxalin-2(1*H*)-one **1a** (0.2 mmol), phenylhydrazine **2a** (0.4 mmol), NaI (0.001mmol) and $g-C_3N_4$ (15 mg) were stirred in EtOH (3 mL) irradiated with a 8 W blue LED for 30 h under an air atmosphere at room temperature. After completion of the reaction, the photocatalyst was separated by centrifugation and washed twice with EtOH, then under vacuum removes the residual solvents, and used for next run.

2.5 Effect of Visible Light Irradiation

The reaction between **1a** and **2a** was conducted under the standard conditions on a 0.2 mmol scale. The mixture was subjected to sequential periods of stirring under visible

light irradiation (8 W blue LED) followed by stirring in the absence of light. At each time point, one reaction system was suspended and the yield was detected by GC-MS.



Figure S3: Visible Light Irradiation on/off experiment

2.6 Calculation of Apparent Quantum Yield

$$E_{\text{photon}} = \frac{hc}{\lambda_{\text{inc}}(455 \text{ nm})} = \frac{6.63 \times 10^{-34} \text{ J.S} \times 3 \times 10^8 \text{ m.s}^{-1}}{455 \times 10^{-9} \text{ m}} = 4.37 \times 10^{-19} \text{ J}$$

 $E_{total} = PSt = 17.47 \times 10^{-3} \text{ W.cm}^{-2} \times 4.78 \text{ cm}^{2} \times 30 \times 3600 \text{ s} = 9.0 \times 10^{3} \text{ J}$

Number of incident photons =
$$\frac{E_{photon}}{E_{tota}}$$
 = $\frac{9.0 \times 10^3 \text{ J}}{4.37 \times 10^{-19} \text{ J}}$ = 2.06x10²²=34.31 mmol
A.Q.Y(%) = $\frac{\text{Number of Product}}{\text{Number of incident photons}}$ = $\frac{0.174 \text{ mmol}}{34.31 \text{ mmol}}$ = 0.5%< 1

Where h (J·s) is Planck's constant, c (m·s⁻¹) is the speed of light and λ inc (m) is the wavelength of the incident light. P (W·cm-2) is the power density of the incident light, S (cm²) is the irradiation area and t (s) is the photoreaction time.

3. Characterization Data of Products

1-methyl-3-phenylquinoxalin-2(1*H*)-one (3aa)²



¹H NMR (500 MHz, CDCl₃) δ 8.38 – 8.23 (m, 2H), 7.95 (dd, J = 8.0, 1.5 Hz, 1H),

 $7.65-7.54\ (m,\ 1H),\ 7.53-7.44\ (m,\ 3H),\ 7.44-7.31\ (m,\ 2H),\ 3.78\ (s,\ 3H).$

¹³C NMR (125 MHz, CDCl₃) δ 154.86, 154.33, 136.22, 133.53, 133.26, 130.61, 130.45, 129.68, 128.21, 123.86, 113.71, 29.43.

Melting Point (Experimental): Value: 138-139 °C

1-ethyl-3-phenylquinoxalin-2(1H)-one (3ba)³



¹H NMR (500 MHz, CDCl₃) δ 8.40 – 8.25 (m, 2H), 7.96 (dd, *J* = 8.3, 1.5 Hz, 1H), 7.61 – 7.52 (m, 1H), 7.48 (p, *J* = 3.7 Hz, 3H), 7.36 (dd, *J* = 8.3, 5.8 Hz, 2H), 4.39 (q, *J* = 7.2 Hz, 2H), 1.43 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 154.32, 154.27, 136.19, 133.56, 132.45, 130.87, 130.40, 129.71, 128.18, 123.64, 113.53, 37.71, 12.54.

1-pentyl-3-phenylquinoxalin-2(1H)-one (3ca)³



¹H NMR (500 MHz, CDCl₃) δ 8.31 (dd, J = 6.7, 3.0 Hz, 2H), 7.96 (d, J = 7.9 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.50 – 7.46 (m, 3H), 7.38 – 7.31 (m, 2H), 4.36 – 4.24 (m, 2H), 1.80 (q, J = 7.8 Hz, 2H), 1.45 (dq, J = 26.0, 7.7 Hz, 4H), 0.94 (t, J = 7.1 Hz, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 154.51, 154.27, 136.21, 133.52, 132.69, 130.82, 130.39, 130.35, 129.70, 128.18, 123.63, 113.70, 42.75, 29.30, 27.10, 22.55, 14.11. **1-benzyl-3-phenylquinoxalin-2(1***H***)-one (3da)²**



¹H NMR (500 MHz, CDCl₃) δ 8.33 – 8.25 (m, 2H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.41 (d, *J* = 4.6 Hz, 3H), 7.35 (t, *J* = 7.7 Hz, 1H), 7.28 – 7.13 (m, 7H), 5.48 (s, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 154.89, 154.32, 136.11, 135.46, 133.47, 132.83, 130.68, 130.55, 130.43, 129.75, 129.04, 128.23, 127.80, 127.08, 123.91, 114.46, 46.23.

ethyl 2-(2-oxo-3-phenylquinoxalin-1(2H)-yl)acetate (3ea)³



¹H NMR (500 MHz, CDCl₃) δ 8.33 (dd, *J* = 6.8, 3.3 Hz, 2H), 7.97 (d, *J* = 7.9 Hz, 1H), 7.57 - 7.45 (m, 4H), 7.37 (t, *J* = 7.7 Hz, 1H), 7.10 (d, *J* = 8.4 Hz, 1H), 5.09 (s, 2H), 4.27 (q, *J* = 7.0 Hz, 2H), 1.29 (t, *J* = 6.9 Hz, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 167.29, 154.40, 153.98, 135.84, 133.29, 132.64, 130.89, 130.59, 130.58, 129.69, 128.20, 124.14, 113.14, 62.19, 43.88, 14.24.

1-allyl-3-phenylquinoxalin-2(1*H*)-one (3fa)³



¹H NMR (500 MHz, CDCl₃) δ 8.34 (dd, J = 6.7, 3.1 Hz, 2H), 7.96 (d, J = 7.9 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.53 – 7.44 (m, 3H), 7.36 (t, J = 7.6 Hz, 1H), 7.31 (d, J = 8.5 Hz, 1H), 6.07 – 5.92 (m, 1H), 5.29 (d, J = 10.2 Hz, 1H), 5.22 (d, J = 17.2 Hz, 1H), 4.97 (d, J = 5.2 Hz, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 154.35, 154.20, 136.06, 133.36, 132.68, 130.76, 130.64, 130.47, 130.34, 129.70, 128.17, 123.82, 118.26, 114.21, 44.84.

Melting Point (Experimental): Value: 98 °C

3-phenyl-1-(prop-2-yn-1-yl)quinoxalin-2(1H)-one (3ga)³



¹H NMR (500 MHz, CDCl₃) δ 8.32 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.96 (d, *J* = 8.0 Hz, 1H), 7.60 (t, *J* = 7.7 Hz, 1H), 7.54 – 7.46 (m, 4H), 7.40 (t, *J* = 7.6 Hz, 1H), 5.12 (d, *J* = 2.6 Hz, 2H), 2.32 (d, *J* = 2.7 Hz, 1H).

¹³C NMR (125 MHz, CDCl₃) δ 154.09, 153.81, 135.86, 133.40, 131.95, 130.71, 130.62, 130.54, 129.69, 128.22, 124.24, 114.16, 77.03, 73.27, 31.78.

3-phenylquinoxalin-2(1*H*)-one (3ha)³



¹H NMR (500 MHz, DMSO-*d*₆) δ 12.59 (s, 1H), 8.44 – 8.21 (m, 2H), 7.95 – 7.84 (m, 1H), 7.60 – 7.47 (m, 4H), 7.34 (t, *J* = 8.0 Hz, 2H).

¹³C NMR (125 MHz, DMSO-*d*₆) δ 154.68, 154.26, 135.68, 132.12, 130.44, 130.31, 129.28, 128.86, 127.96, 123.52, 115.18.

Melting Point (Experimental): Value: 243 °C

6-(tert-butyl)-1-methyl-3-phenylquinoxalin-2(1*H*)-one (3ia)



¹H NMR (500 MHz, CDCl₃) δ 8.36 – 8.24 (m, 2H), 7.96 (q, *J* = 1.8 Hz, 1H), 7.63 (dq, *J* = 8.9, 1.8 Hz, 1H), 7.52 – 7.42 (m, 3H), 7.36 – 7.22 (m, 3H), 3.76 (s, 3H), 1.41 (s, 9H).

¹³C NMR (125 MHz, CDCl₃) δ 154.84, 154.26, 147.19, 136.35, 132.93, 131.18, 130.29, 129.59, 128.25, 128.19, 126.95, 113.36, 34.60, 31.44, 29.38.

6-methoxy-1-methyl-3-phenylquinoxalin-2(1H)-one (3ja)³



¹H NMR (500 MHz, CDCl₃) δ 8.25 – 8.16 (m, 1H), 7.42 – 7.35 (m, 2H), 7.31 (d, J = 2.8 Hz, 1H), 7.14 (d, J = 9.1 Hz, 1H), 7.09 (dd, J = 9.1, 2.8 Hz, 1H), 3.80 (s, 2H), 3.65 (s, 1H).

¹³C NMR (125 MHz, CDCl₃) δ 156.12, 154.63, 154.45, 136.27, 133.89, 130.38, 129.63, 128.15, 127.77, 119.79, 114.58, 111.65, 55.86, 29.51.

Melting Point (Experimental): Value: 153-154 °C

6-chloro-1-methyl-3-phenylquinoxalin-2(1H)-one (3ka)³



¹H NMR (500 MHz, CDCl₃) δ 8.36 – 8.25 (m, 2H), 7.90 (d, *J* = 2.3 Hz, 1H), 7.54 – 7.42 (m, 4H), 7.22 (d, *J* = 8.9 Hz, 1H), 3.71 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 155.17, 154.42, 135.72, 133.64, 132.11, 130.81, 130.28, 129.74, 129.68, 129.06, 128.20, 114.81, 29.56.

6-bromo-1-methyl-3-phenylquinoxalin-2(1H)-one (3la)³



¹H NMR (500 MHz, CDCl₃) δ 8.35 – 8.24 (m, 2H), 8.07 (t, J = 1.7 Hz, 1H), 7.65 – 7.60 (m, 1H), 7.48 (d, J = 6.6 Hz, 3H), 7.18 (d, J = 8.8 Hz, 1H), 3.72 (s, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 155.17, 154.45, 135.72, 133.99, 133.04, 132.80, 132.57, 130.85, 129.76, 128.23, 116.35, 115.12, 29.57.

1,6,7-trimethyl-3-phenylquinoxalin-2(1H)-one (3ma)²



¹H NMR (500 MHz, CDCl₃) δ 8.21 (dd, J = 6.4, 2.6 Hz, 2H), 7.60 (s, 1H), 7.38 (dd, J = 5.5, 1.9 Hz, 3H), 6.99 (s, 1H), 3.64 (s, 3H), 2.34 (s, 3H), 2.27 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 154.89, 153.00, 140.42, 136.48, 132.78, 131.67, 131.52, 130.57, 130.08, 129.55, 128.11, 114.24, 29.30, 20.74, 19.31.

1-methyl-3-(p-tolyl)quinoxalin-2(1H)-one (3ab)²



¹H NMR (500 MHz, CDCl₃) δ 8.24 (d, *J* = 7.9 Hz, 2H), 7.93 (d, *J* = 8.0 Hz, 1H), 7.55 (t, *J* = 7.8 Hz, 1H), 7.38 – 7.31 (m, 2H), 7.29 (d, *J* = 7.9 Hz, 2H), 3.77 (s, 3H), 2.42 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 154.92, 154.20, 140.77, 133.46, 133.30, 130.49, 130.46, 130.19, 129.67, 129.64, 128.98, 128.94, 123.81, 113.68, 29.42, 21.67.

3-(4-isopropylphenyl)-1-methylquinoxalin-2(1H)-one (3ac)³



¹H NMR (500 MHz, CDCl₃) δ 8.23 (d, *J* = 8.0 Hz, 2H), 7.94 (d, *J* = 8.1 Hz, 1H), 7.56 (t, *J* = 7.9 Hz, 1H), 7.35 (q, *J* = 6.8, 5.8 Hz, 4H), 3.78 (s, 3H), 2.97 (h, *J* = 7.0 Hz, 1H), 1.29 (d, *J* = 7.1 Hz, 6H).

¹³C NMR (125 MHz, CDCl₃) δ 154.93, 154.38, 151.59, 133.85, 133.43, 133.33, 130.49, 130.19, 129.71, 125.40, 123.81, 113.68, 34.31, 29.43, 23.98.



¹H NMR (500 MHz, CDCl₃) δ 8.24 (d, J = 8.2 Hz, 2H), 8.06 – 7.89 (m, 1H), 7.68 – 7.47 (m, 3H), 7.46 – 7.29 (m, 2H), 3.77 (s, 3H), 1.37 (s, 9H).

¹³C NMR (125 MHz, CDCl₃) δ 154.90, 154.33, 153.73, 133.45, 133.41, 133.32, 130.48, 130.17, 129.39, 125.25, 123.77, 113.66, 34.98, 31.34, 29.40.

3-(4-methoxyphenyl)-1-methylquinoxalin-2(1*H*)-one (3ae)²



¹H NMR (500 MHz, CDCl₃) δ 8.32 (d, *J* = 8.5 Hz, 2H), 7.84 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.33 – 7.23 (m, 2H), 6.92 (d, *J* = 8.6 Hz, 2H), 3.81 (s, 3H), 3.69 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 161.63, 155.00, 153.37, 133.33, 133.28, 131.51, 130.29, 129.90, 128.91, 123.80, 113.64, 113.62, 55.52, 29.41.

1-methyl-3-(4-(trifluoromethoxy)phenyl)quinoxalin-2(1H)-one (3af)³



¹H NMR (500 MHz, CDCl₃) δ 8.46 (d, J = 8.1 Hz, 2H), 7.96 (dd, J = 8.0, 1.5 Hz, 1H), 7.73 (d, J = 8.1 Hz, 2H), 7.65 – 7.57 (m, 1H), 7.44 – 7.36 (m, 2H), 3.79 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 154.70, 152.74, 139.43, 133.65, 133.12, 131.92 (J = 125.0 Hz) 131.20, 130.89, 130.03, 125.09 (J = 32.5 Hz) 124.15, 113.86, 29.52. ¹⁹F NMR (471 MHz, CDCl₃) δ -62.79.

3-(4-fluorophenyl)-1-methylquinoxalin-2(1*H*)-one (3ag)²



¹H NMR (500 MHz, CDCl₃) δ 8.39 (dd, J = 8.5, 5.6 Hz, 2H), 7.93 (d, J = 8.0 Hz, 1H), 7.58 (t, J = 7.8 Hz, 1H), 7.41 – 7.32 (m, 2H), 7.16 (t, J = 8.5 Hz, 2H), 3.77 (s, 3H). ¹³C NMR (125 MHz, CDCl3) δ 164.22 (J = 17.5 Hz), 154.69, 152.79, 133.33, 133.03, 132.20 (J = 7.5 Hz), 131.85 (J = 17.5 Hz), 130.41 (J = 7.5 Hz), 123.84, 115.16 114.99, 113.62, 29.34.

¹⁹F NMR (471 MHz, CDCl₃) δ -110.01 (d, J = 7.9 Hz).

3-(4-chlorophenyl)-1-methylquinoxalin-2(1*H*)-one (3ah)¹



¹H NMR (500 MHz, CDCl₃) δ 8.43 – 8.26 (m, 2H), 7.94 (d, *J* = 8.0 Hz, 1H), 7.59 (t, *J* = 7.8 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.43 – 7.31 (m, 2H), 3.84 – 3.72 (m, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 154.77, 152.85, 136.69, 134.56, 133.49, 133.15, 131.12, 130.75, 130.64, 128.45, 124.06, 113.80, 29.51.

3-(4-bromophenyl)-1-methylquinoxalin-2(1H)-one (3ai)³



¹H NMR (500 MHz, CDCl₃) δ 8.33 – 8.22 (m, 2H), 7.94 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.65 – 7.56 (m, 3H), 7.44 – 7.32 (m, 2H), 3.77 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 154.73, 152.91, 135.03, 133.53, 133.16, 131.41, 131.35, 130.77, 130.67, 125.25, 124.04, 113.79, 29.49.

3-(4-iodophenyl)-1-methylquinoxalin-2(1*H*)-one (3aj)³



¹H NMR (500 MHz, CDCl₃) δ 8.17 – 8.06 (m, 2H), 7.93 (dd, J = 8.1, 1.7 Hz, 1H), 7.85 – 7.78 (m, 2H), 7.64 – 7.55 (m, 1H), 7.42 – 7.30 (m, 2H), 3.77 (s, 2H).

¹³C NMR (125 MHz, CDCl₃) δ 154.67, 137.38, 135.61, 133.50, 133.13, 131.37, 130.78, 130.66, 129.67, 124.02, 113.78, 97.57, 29.47.

1-methyl-3-(4-(trifluoromethyl)phenyl)quinoxalin-2(1*H*)-one (3ak)²



¹H NMR (471 MHz, CDCl₃) δ 8.41 (d, J = 8.5 Hz, 2H), 7.94 (dd, J = 7.9, 1.4 Hz, 1H), 7.74 – 7.56 (m, 1H), 7.42 – 7.34 (m, 2H), 7.32 (d, J = 8.4 Hz, 2H), 3.78 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 154.76, 152.69, 150.84, 134.68, 133.55, 133.14, 131.48, 130.83, 130.69, 124.06, 120.61 (d, J = 255 Hz), 120.37, 113.81, 29.50. ¹⁹F NMR (500 MHz, CDCl₃) δ -57.57.

1-methyl-3-(m-tolyl)quinoxalin-2(1*H*)-one (3al)²



¹H NMR (500 MHz, CDCl₃) δ 8.09 (t, *J* = 3.3 Hz, 2H), 7.95 (d, *J* = 8.0 Hz, 1H), 7.57 (t, *J* = 7.8 Hz, 1H), 7.40 - 7.28 (m, 3H), 3.77 (s, 3H), 2.45 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 154.88, 154.59, 137.79, 136.15, 133.48, 133.26, 131.28, 130.56, 130.36, 130.12, 128.12, 126.88, 123.83, 113.69, 29.42, 21.69.

1-methyl-3-(o-tolyl)quinoxalin-2(1H)-one (3am)²



¹H NMR (500 MHz, CDCl₃) δ 7.94 (d, *J* = 7.9 Hz, 1H), 7.61 (t, *J* = 7.7 Hz, 1H), 7.46 (d, *J* = 7.4 Hz, 1H), 7.41 – 7.33 (m, 3H), 7.30 (d, *J* = 7.2 Hz, 2H), 3.78 (s, 3H), 2.35 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 158.54, 154.69, 136.96, 136.25, 133.71, 133.01, 130.68, 130.66, 130.57, 129.46, 129.30, 125.73, 123.87, 113.82, 29.50, 20.06.

1-methyl-3-(naphthalen-2-yl)quinoxalin-2(1H)-one (3an)³



¹H NMR (500 MHz, CDCl₃) δ 9.08 (s, 1H), 8.48 – 8.36 (m, 1H), 7.99 (d, *J* = 7.9 Hz, 2H), 7.93 (d, *J* = 8.7 Hz, 1H), 7.87 (d, *J* = 7.7 Hz, 1H), 7.63 – 7.47 (m, 3H), 7.40 (t, *J* = 7.6 Hz, 1H), 7.35 (d, *J* = 8.4 Hz, 1H), 3.80 (s, 3H).

¹³C NMR (125 MHz, CDCl₃) δ 155.02, 153.61, 134.39, 133.48, 133.41, 133.31, 133.07, 130.69, 130.60, 130.47, 129.53, 127.72, 127.67, 127.36, 126.26, 126.23, 123.92, 113.73, 29.46.

4. References

[1] S. J. Song, X. J. Shi, Y. S. Zhu, Q. L. Ren, P. Zhou, J. D. Zhou and J. J. Li, *J. Org. Chem.*, 2022, **7**, 4764 - 4776.

[2] M. Tian, S. Y. Liu, X. B. Bu, J. P. Yu, and X. B. Yang, Chem. Eur. J. 2020, 26, 369.

[3] L. Y. Xie, S. Peng, L. H. Yang, C. Peng, Y. W. Lin, X. Y. Yu, Z. Cao, Y. Y. Peng and W. M. He *Green Chem.*, 2021, **23**, 374 - 378.

5. ¹H, ¹³C and ¹⁹F NMR Spectra of Products

1-methyl-3-phenylquinoxalin-2(1*H*)-one (3aa)

¹H NMR (500 MHz, CDCl₃) spectrum of **3aa**



f1 (ppm)

1-ethyl-3-phenylquinoxalin-2(1*H*)-one (3ba)



1-pentyl-3-phenylquinoxalin-2(1H)-one (3ca)



1-benzyl-3-phenylquinoxalin-2(1*H*)-one (3da)



¹H NMR (500 MHz, CDCl₃) spectrum of **3da**

ethyl 2-(2-oxo-3-phenylquinoxalin-1(2*H*)-yl)acetate (3ea)



1-allyl-3-phenylquinoxalin-2(1*H*)-one (3fa)





3-phenyl-1-(prop-2-yn-1-yl)quinoxalin-2(1H)-one (3ga)

3-phenylquinoxalin-2(1*H*)-one (3ha)



$^{13}C{^{1}H}$ NMR (125 MHz, DMSO- d_6) spectrum of **3ha**



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -: fl (ppm)

6-(tert-butyl)-1-methyl-3-phenylquinoxalin-2(1*H*)-one (3ia)

¹H NMR (500 MHz, CDCl₃) spectrum of **3ia**



6-methoxy-1-methyl-3-phenylquinoxalin-2(1*H*)-one (3ja)



6-chloro-1-methyl-3-phenylquinoxalin-2(1*H*)-one (3ka)



6-bromo-1-methyl-3-phenylquinoxalin-2(1*H*)-one (3la)

¹H NMR (500 MHz, CDCl₃) spectrum of **3la**



1,6,7-trimethyl-3-phenylquinoxalin-2(1H)-one (3ma)



fl (ppm)

1,6,7-trimethyl-3-phenylquinoxalin-2(1H)-one (3ab)



3-(4-isopropylphenyl)-1-methylquinoxalin-2(1*H*)-one (3ac)

¹H NMR (500 MHz, CDCl₃) spectrum of **3ac**



3-(4-(tert-butyl)phenyl)-1-methylquinoxalin-2(1*H*)-one (3ad)





3-(4-methoxyphenyl)-1-methylquinoxalin-2(1*H*)-one (3ae)



1-methyl-3-(4-(trifluoromethoxy)phenyl)quinoxalin-2(1*H*)-one (3af)





¹⁹F NMR (471 MHz, CDCl₃) spectrum of **3af**



3-(4-fluorophenyl)-1-methylquinoxalin-2(1*H*)-one (3ag)

^1H NMR (500 MHz, CDCl₃) spectrum of 3ag





40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140 -145 -15 f1 (ppm)

3-(4-chlorophenyl)-1-methylquinoxalin-2(1*H*)-one (3ah)

 ^1H NMR (500 MHz, CDCl₃) spectrum of 3ah



3-(4-bromophenyl)-1-methylquinoxalin-2(1*H*)-one (3ai)

¹H NMR (500 MHz, CDCl₃) spectrum of **3ai**



3-(4-iodophenyl)-1-methylquinoxalin-2(1*H*)-one (3aj)





1-methyl-3-(4-(trifluoromethyl)phenyl)quinoxalin-2(1*H*)-one (3ak)







1-methyl-3-(m-tolyl)quinoxalin-2(1H)-one (3al)

^1H NMR (500 MHz, CDCl₃) spectrum of **3al**



¹³C{¹H} NMR (125 MHz, CDCl₃) spectrum of **3al**



1-methyl-3-(o-tolyl)quinoxalin-2(1*H*)-one (3am)

¹H NMR (500 MHz, CDCl₃) spectrum of **3am**





1-methyl-3-(naphthalen-2-yl)quinoxalin-2(1*H*)-one (3an)





¹³C{¹H} NMR (125 MHz, CDCl₃) spectrum of **3an**



fl (ppm)